We are live on ! Find out more
Perceptive Advisors

Perceptive Advisors Portfolio holdings

AUM $6.66B Turnover 32.23%
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+43.17%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$3.56B
AUM Growth
+$116M
Cap. Flow
-$205M
Cap. Flow %
-5.76%
Top 10 Hldgs %
45.81%
Holding
127
New
13
Increased
20
Reduced
25
Closed
31
Avg Time Held Equity + Options
2.1 years
Top 10 Avg Time Held Equity + Options
1.5 years
Top 20 Avg Time Held Equity + Options
1.5 years
Avg Time Held Equity only
2.2 years
Top 10 Avg Time Held Equity only
1.5 years
Top 20 Avg Time Held Equity only
1.5 years

Sector Composition

Rank Sector Weight
1 Healthcare 97.34%
2 Miscellaneous 2.57%
3 Financials 0.08%
4 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
GBT
126
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-2,322,247
Closed -$158M –
CTIC
127
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
– –
-735,165
Closed -$4.28M –

Similar funds

Perceptive Advisors's Q4 2022 Portfolio in Review

As of Q4 2022, Perceptive Advisors held 127 positions worth $3.56B, up 3.4% from $3.45B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Perceptive Advisors withdrew a net $205M in Q4 2022, closing 31 positions and reducing 25 holdings. Its most notable exit was Global Blood Therapeutics, Inc., an estimated $158M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Perceptive Advisors opened a new position in Horizon Therapeutics Public Limited Company Ordinary Shares worth $109M.

  • Perceptive Advisors's largest Q4 2022 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 960,000 shares worth $109M.
  • Perceptive Advisors added most to Sarepta Therapeutics in Q4 2022, an estimated $45.9M increase.
  • Perceptive Advisors's biggest Q4 2022 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $38.4M.
  • Perceptive Advisors fully exited Global Blood Therapeutics, Inc. in Q4 2022, selling an estimated $158M.
  • Perceptive Advisors's ten largest holdings make up 46% of its $3.56B portfolio in Q4 2022.
  • Perceptive Advisors opened 13 new positions and closed 31 in Q4 2022.
  • Perceptive Advisors's portfolio value rose 3.4% quarter-over-quarter to $3.56B.

Based on Perceptive Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.